Kingy AI
Subscribe, 2.1M subscribersWork with Kingy

Breakthrough Tracker record

FDA approves the first direct muscle-targeted add-on therapy for spinal muscular atrophy

FDA approved apitegromab for adults and children aged two years or older with spinal muscular atrophy who already receive an SMN2-targeted treatment. The pivotal 52-week trial found a 1.8-point adjusted motor-scale benefit at the approved dose.

← Back to the filtered Breakthrough Tracker

Stable ID
medicine-apitegromab-sma-fda-approval-2026
Revision
medicine-apitegromab-sma-fda-approval-2026.v1
Field
Medicine · Neuromuscular disease and myostatin inhibition
Evidence
Tier 1 · Peer reviewed: Yes
Record state
Current · FDA approved
Last checked

AI role

No substantive AI role was disclosed in the regulator decision or inspected trial records.

Record details

Problem or result
Add-on muscle-targeted treatment for spinal muscular atrophy
Authors
Thomas O. Crawford, Laurent Servais, Eugenio Mercuri and the SAPPHIRE Study Group
Institutions
International SAPPHIRE trial sites; Scholar Rock; neuromuscular centres in the United States and Europe
Result date
FDA approval September 11, 2026

Why it matters

Existing disease-modifying SMA therapies increase survival motor neuron protein. Apitegromab is the first approval to complement them by directly inhibiting latent myostatin in muscle.

Limits

It is an add-on, not a cure or replacement for SMN-directed therapy. The mean gain was modest, the pivotal primary population was non-ambulatory children aged 2–12, and longer-term functional durability remains uncertain.

Sources

  1. Regulator: FDA approval announcement for apitegromab
  2. Primary: SAPPHIRE phase 3 PubMed record
  3. Primary: Lancet Neurology SAPPHIRE trial article

Correction and revision history

  1. 2026-10-02 — Added after primary-source, scope, status, AI-role and limitation review.

Machine-readable: JSON v1 · CSV v1 · Schema v1

This individual record remains noindex until a story-specific featured image passes Kingy’s rendered-pixel visual review. The source-linked tracker hub remains the public index.